|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/36 | (2006.01) |
| A61K 38/48 | (2006.01) | ||
| A61K 9/19 | (2006.01) | ||
| C07K 14/00 | (2006.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 39/02 | (2006.01) | ||
| A61P 7/00 | (2006.01) | ||
| A61K 47/18 | (2017.01) | ||
| A61K 47/26 | (2006.01) | ||
| C12N 9/64 | (2006.01) |
| (11) | Number of the document | 3419650 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17757375.5 |
| Date of filing the European patent application | 2017-02-24 | |
| (97) | Date of publication of the European application | 2019-01-02 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/019502 |
| Date | 2017-02-24 |
| (87) | Number | WO 2017/147522 |
| Date | 2017-08-31 |
| (30) | Number | Date | Country code |
| 201662299369 P | 2016-02-24 | US |
| (72) |
NGUYEN, Phuong M. , US
|
| (73) |
Alexion Pharmaceuticals, Inc. ,
121 Seaport Boulevard, Boston, MA 02210,
US
|
| (54) | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE |
| LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE |